Hyderabad, India and Princeton, NJ, USA. July 23, 2019 — Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE:
DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the
launch of Ramelteon Tablets, 8 mg, a therapeutically equivalent generic version of Rozerem® (ramelteon, 8 mg)
Tablets, approved by the U.S. Food and Drug Administration (USFDA).
The Rozerem® brand had U.S. sales of approximately $91.3 million MAT for the most recent twelve months ending in
May 2019 according to IQVIA Health*.
Dr. Reddy’s Ramelteon Tablets, are available as 8 mg tablets in bottle count sizes of 30, 100, and 1000.
Rozerem® is a trademark of Takeda Pharmaceutical Company Limited.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal,
cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major
markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
